Improved Markers of Cholestatic Liver Injury in Patients With Primary Biliary Cholangitis Treated With Obeticholic Acid and Bezafibrate
Open accessAbstract
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Several currently explored drugs (eg, NR ligands) simultaneously target multiple key pathogenetic processes and may show synergistic effects when combined in management of cholestatic and fatty liver diseases, for example, combining FXR and PPAR ligands in PBC and NASH.
“Several of the currently explored drugs (eg, NR ligands) simultaneously target multiple key pathogenetic processes and may show even synergistic effects when combined in the management of these disorders, for example, combining FXR and PPAR ligands in PBC232 233 and NASH.234”
From Novel therapeutic targets for cholestatic and fatty liver disease (2022) · cites this paper as [233]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509840 · Cited by 1,131 · cited 2× · see citing works
“(1) Obeticholic acid (OCA) is the approved second-line therapy if ursodeoxycholic acid (UDCA) fails, but its use may worsen pruritus.(2) Adding bezafibrate to UDCA improved biochemical markers of cholestatic liver injury and decreased pruritus severity.”
BackgroundMethodSelf-citation
Flagged first, then by citations
Research works printed but not linked: 3
- Murillo Perez CF, Harms MH, Lindor KD, van Buuren HR, Hirschfield GM, Corpechot C, et al. Goals of Treatment for Improved Survival in Primary Biliary Cholangitis. Am J Gastroenterol 2020;115:1066-1074.
- Corpechot C, Chazouillères O, Rousseau A, Le Gruyer A, Habersetzer F, Mathurin P, et al. A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis. N Engl J Med 2018;378:2171-2181.
- Reig A, Sesé P, Parés A. Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response. Am J Gastroenterol 2018;113:49-55. Accepted Article
Cited by
Sorted by citations
Novel therapeutic targets for cholestatic and fatty liver disease
Trauner, M., & Fuchs, C. D. (2022) · Gut · doi:10.1136/gutjnl-2021-324305 · Cited by 204 · see citing works
Advancing care in primary biliary cholangitis: emerging insights and novel therapies
Vögelin, M., & Kremer, A. E. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2516622 · Cited by 5 · see citing works
- Authors
- Smets, L., Verbeek, J., Korf, H., van der Merwe, S., & Nevens, F.
- Affiliations
- KU Leuven (BE)
- Laboratory of Hepatology,CHROMETA Department,KU Leuven,Leuven,Belgium
- Corresponding author
- Smets, Lena
- Venue
- Hepatology
- Published
- 2021-05-25
- Volume
- 73
- Issue
- 6
- Pages
- 2598-2600
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W3097914939
- Cited by
- 34
- References
- 1
- Citations by year
- 2026: 2 · 2025: 12 · 2024: 10 · 2023: 3 · 2022: 4 · 2021: 3
- FWCI
- 1.47
- Type
- journal article
- Language
- en
- Open access
- green
- lirias.kuleuven.be
- Licence
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Lirias (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Keywords
- primary biliary cirrhosis, obeticholic acid, bezafibrate, cholestatic liver injury, liver injury biomarkers, drug-induced liver injury, combination therapy
- MeSH terms
- Alkaline Phosphatase, Hypolipidemic Agents, Bezafibrate, Bilirubin, Chenodeoxycholic Acid, Cholestasis, Cholesterol, Dose-Response Relationship, Drug, Drug Interactions, Female, Humans, Liver Cirrhosis, Biliary, Liver Function Tests, Male, Middle Aged, Pruritus, Treatment Outcome, Drug Monitoring
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
